Industry Briefs: February 4, 2013

Company News

Bend Research has received certification of compliance with European Union GMP regulations. The broad certification, which was granted by Sweden’s Medical Products Agency, covers Bend Research’s manufacture of clinical pharmaceutical supplies for human consumption and testing of those supplies at the company’s GMP facilities. Read More

Cytovance Biologics, a contract manufacturer of mammalian and microbial biologics, plans to expand its current mammalian production capabilities to include a 1000-L SUB bioreactor, a 5000-L stainless-steel bioreactor and an automated fill/finish line. Read More

Dalton Pharma Services, a provider of drug discovery, development, and manufacturing services to pharmaceutical and biotechnology companies, has begun the first stage of its aseptic-filling expansion plan. The initial stage, which commenced in January 2013, will add high-speed, sterile vial processing and washing, an upgraded high-purity water system, expanded vial depyrogenation capability, additional lyophilization capacity, and automated vial-inspection capability. Read More

Elan Corporation, through its wholly owned subsidiary, Elan Science Three Limited, agreed to sell, on customary terms, all of its remaining 7.75 million ordinary shares of Alkermes through Jefferies & Company pursuant to Rule 144 under the US Securities Act of 1933. The sale is expected to close on Feb. 6, 2013. Read More

Kemwell Biopharma has completed a successful FDA inspection. Read More

NSF International, an independent global public health and safety organization, has acquired the INASSA Group of Lima, Peru, which is comprised of three segments: technical analysis, laboratory, and sanitation. It is known as International Analytical Services S.A.C., (INASSA), Environmental Laboratories Peru S.A.C. (Envirolab) and Servicios Integrales de Saneamiento S.A.C. (Servisanea). The INASSA Group will now be known as NSF-INASSA, NSF-Envirolab and NSF-Servisanea. Read More

Patheon has announced plans for additional investment in its Milton Park facility located in Oxfordshire, United Kingdom. The facility is a dedicated pharmaceutical development services facility focused on early development projects. Read More

Teva Pharmaceutical Industries has terminated of its collaboration with CureTech, effective Jan. 31, 2013. CureTech’s CT-011 is a humanized monoclonal antibody being developed as a treatment for hematological malignancies and solid tumors. CT-011 was assessed in several Phase I and II clinical studies in various cancer indications including diffuse large B-cell lymphoma, colon cancer, metastatic melanoma, and additional investigator initiated studies. Teva entered into agreements with CureTech in 2006. Teva intends to book a noncash net charge of $109 million as a result of the impairment of its investment in CureTech. Read More

People News

Clondalkin Group, a producer of packaging products and services, has appointed David Lennon as global CEO of its pharmaceutical and healthcare division. Read More

Metrics has appointed Joe Cascone as senior director of operations. Read More

Metrics has appointed Joseph E. Cobb, Jr. as director of pharmaceutical development. Read More

Metrics has named Thomas B. Gold vice-president of pharmaceutical development. Read More